E 7107
Alternative Names: E7107Latest Information Update: 14 Dec 2009
At a glance
- Originator Eisai Co Ltd; Mercian
- Developer Eisai Co Ltd
- Class Antineoplastics; Cytostatic antibiotics; Macrolides
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Solid tumours
Most Recent Events
- 14 Nov 2009 Adverse events, pharmacokinetics, pharmacodynamics and efficacy data from a phase I trial in Solid tumours presented at the 21st AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2009)
- 01 Apr 2009 Suspended - Phase-I for Solid tumours in USA (IV)
- 08 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section